Conduit Pharmaceuticals (CDT) Stock Analysis: AI Score & Alternative Data
CDT alt-data: revenue climbing, headcount lagging
Is Conduit Pharmaceuticals a buy right now? The alternative data says hold. This CDT stock analysis is built on the 25+ alternative data signals AltIndex tracks on Conduit Pharmaceuticals every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 48/100: a Hold. The stock trades at $0.25 with a $3M market cap.
The bullish side of the 90-day ledger: revenue up 11.9% YoY to $750M, and Reddit mentions up 600.0% to 7 a day. The drag: headcount (according to LinkedIn) down 66.7% to 1 employees, and sentiment down 32.0% to 68/100. That tension is what keeps the score mid-range.
Every signal links to its own page with full history, the CDT technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on CDT is just below.
Conduit Pharmaceuticals AI Stock Analysis
Conduit Pharmaceuticals is a company operatively engaged in the pharmaceutical sector, focusing on the development, manufacturing, and marketing of novel therapeutics. Its primary focus is on innovation and delivering value-driven initiatives in healthcare.
Analysis generated September 1, 2026.
Recent Conduit Pharmaceuticals Stock Alerts
|
Conduit Pharmaceuticals | September 11 Price is down by -27.6% in the last 24h. |
|
Conduit Pharmaceuticals | September 10 Price is down by -34.8% in the last 24h. |
|
Conduit Pharmaceuticals | September 4 Price is down by -9.5% in the last 24h. |
|
Conduit Pharmaceuticals | September 3 Price is down by -8.8% in the last 24h. |
Conduit Pharmaceuticals Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 0 | N/A | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 1 | 66.7% | |
| Sentiment | 68 | 32.0% | |
| Reddit Mentions | 7 | 600.0% | |
| X Mentions | 9 | 65.4% | |
| Stocktwits Mentions | 516 | 2,050.0% | |
| News Mentions | 0 | 100.0% | |
| Stocktwits Subscribers | 4K | 7.5% | |
| 4chan Mentions | 0 | N/A |
About Conduit Pharmaceuticals (CDT)
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
| Price | $0.25 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $3M |
| Year Range | $0 – $1,798 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Conduit Pharmaceuticals News
View more →
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to SugarcaneJuly 20 - GlobeNewswire |
|
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form DevelopmentJune 26 - GlobeNewswire |
|
CDT Equity Announces Debt Update and New Loan FacilityJune 16 - GlobeNewswire |
|
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature AgentMarch 5 - GlobeNewswire |
|
 |
CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset StrategyFebruary 19 - Yahoo |
See Conduit Pharmaceuticals’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for CDT, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEConduit Pharmaceuticals Earnings & Financial Performance
View all earnings →Conduit Pharmaceuticals Insider Trading Activity
View all →| Taylor Mark Andrew filed to sell 593,289 shares at $0.0. Jun 18 '26 |
| Taylor Mark Andrew filed to sell 0 shares at $0.0. Jun 18 '26 |
| Taylor Mark Andrew filed to sell 0 shares at $0.0. Jun 18 '26 |
| Nirland Ltd filed to sell 6,092,000 shares at $0.0. Oct 7 '24 |
| Nirland Ltd filed to sell 7,031,009 shares at $0.0. Oct 4 '24 |
Conduit Pharmaceuticals Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Conduit Pharmaceuticals
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
China SXT PharmaceuticalsSXTC |
$2.56 32.6% | $3M | 50 |
 |
Aptevo TherapeuticsAPVO |
$1.82 0.6% | $3M | 50 |
 |
Calidi BiotherapeuticsCLDI |
$1.24 5.3% | $3M | 45 |
 |
60 DegreesSXTP |
$0.91 2.4% | $3M | 49 |
 |
BioRestorative TherapiesBRTX |
$2.67 3.3% | $4M | 50 |
Explore Conduit Pharmaceuticals Data
Frequently Asked Questions: Conduit Pharmaceuticals (CDT)
Conduit Pharmaceuticals has an AltIndex AI Score of 48/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
48/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Conduit Pharmaceuticals (CDT) stock is $0.25 with a market cap of $3M.
As of today, Conduit Pharmaceuticals’s PE (Price to Earnings) ratio is —.
View the latest Conduit Pharmaceuticals insider transactions to see recent buying and selling activity by company executives and directors.
Check the Conduit Pharmaceuticals congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The CDT stock price chart above shows Conduit Pharmaceuticals’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Conduit Pharmaceuticals technical analysis for RSI, moving averages, and more.
See the stocks similar to Conduit Pharmaceuticals section on this page for companies in the same industry ranked by market cap and AI Score.
